Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.3035
Abstract: In combination with lenalidomide and dexamethasone (KRd), Carfilzomib has been approved for the treatment of relapsed and refractory multiple myeloma (RRMM) on ASPIRE trial. Efficacy and safety of the triplet are still the object of… read more here.
Keywords: krd; therapy; dexamethasone krd; lenalidomide dexamethasone ... See more keywords
Stem Cell Mobilization and Autograft Purity with Novel Induction Regimens in Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2019 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2018.12.092
Abstract: Background High-dose chemotherapy and autologous stem cell transplantation (ASCT) remains the standard-of-care in transplant-eligible patients with multiple myeloma (MM). Bortezomib with lenalidomide and dexamethasone (RVD) is the most common triplet induction regimen for patients with… read more here.
Keywords: rvd; stem cell; krd; cell ... See more keywords
VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-124403
Abstract: Introduction Immunomodulatory agents (IMiD's) are associated with an increased risk of venous thromboembolism (VTE), particularly when combined with high dose steroids. Studies evaluating the use of lenalidomide-bortezomib-dexamethasone (RVD) and carfilzomib-lenalidomide-dexamethasone (KRD) in the frontline setting… read more here.
Keywords: arm; krd; asa; research funding ... See more keywords
High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.4533.4533
Abstract: Introduction In a phase 2 study designed to assess efficacy of extended treatment (tx) with KRd (carfilzomib [CFZ], lenalidomide [LEN], and dexamethasone [DEX]) plus autologous stem cell transplantation (ASCT), we reported high rates of deep… read more here.
Keywords: krd; research; research funding; honoraria ... See more keywords
Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.8002
Abstract: 8002 Background: High and comparable rates of MRD negativity were seen in NDMM pts after 4 28-day induction cycles with KRd followed by ASCT and 4 KRd consolidation (KRd_ASCT_KRd) and after 12 KRd cycles (KRd12),… read more here.
Keywords: krd asct; krd krd12; krd; risk ... See more keywords
Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone
Sign Up to like & getrecommendations! Published in 2022 at "AntiCancer Research"
DOI: 10.21873/anticanres.16145
Abstract: Background/Aim: Carfilzomib, lenalidomide, and dexamethasone (KRD) therapy is widely used for patients with relapse/refractory multiple myeloma (RRMM). However, the response in patients who underwent assessment for measurable residual disease (MRD) has not been elucidated in… read more here.
Keywords: krd; krd therapy; mrd; response ... See more keywords